Cargando…

Anti-Inflammatory Effects of the Iron Chelator, DIBI, in Experimental Acute Lung Injury

Iron plays a critical role in the immune response to inflammation and infection due to its role in the catalysis of reactive oxygen species (ROS) through the Haber-Weiss and Fenton reactions. However, ROS overproduction can be harmful and damage healthy cells. Therefore, iron chelation represents an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehmann, Christian, Alizadeh-Tabrizi, Nazli, Hall, Stefan, Faridi, Sufyan, Euodia, Irene, Holbein, Bruce, Zhou, Juan, Chappe, Valerie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268372/ https://www.ncbi.nlm.nih.gov/pubmed/35807282 http://dx.doi.org/10.3390/molecules27134036

Ejemplares similares

Iron Chelator DIBI Suppresses Formation of Ciprofloxacin-Induced Antibiotic Resistance in Staphylococcus aureus
por: Allan, David S., et al.
Publicado: (2022)

Iron Withdrawal with DIBI, a Novel 3-Hydroxypyridin-4-One Chelator Iron-Binding Polymer, Attenuates Macrophage Inflammatory Responses
por: Ghassemi-Rad, Javad, et al.
Publicado: (2023)

Novel Iron-Chelator DIBI Inhibits Staphylococcus aureus Growth, Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics in vitro
por: Parquet, Maria del Carmen, et al.
Publicado: (2018)

Antimicrobial Activity of the Iron-Chelator, DIBI, against Multidrug-Resistant Canine Methicillin-Susceptible Staphylococcus pseudintermedius: A Preliminary Study of Four Clinical Strains
por: Nocera, Francesca Paola, et al.
Publicado: (2022)

Comparison of Treatment Effects of Different Iron Chelators in Experimental Models of Sepsis
por: Lehmann, Christian, et al.
Publicado: (2021)

Iron Chelation as a Potential Therapeutic Approach in Acute Lung Injury
por: Zhang, Xiyang, et al.
Publicado: (2023)

The Utility of Iron Chelators in the Management of Inflammatory Disorders
por: Lehmann, C., et al.
Publicado: (2015)

Iron Chelation in Murine Models of Systemic Inflammation Induced by Gram-Positive and Gram-Negative Toxins
por: Fokam, Danielle, et al.
Publicado: (2020)

Selective CB(2) Receptor Agonist, HU-308, Reduces Systemic Inflammation in Endotoxin Model of Pneumonia-Induced Acute Lung Injury
por: Hall, Stefan, et al.
Publicado: (2022)

Intravital Imaging of Pulmonary Immune Response in Inflammation and Infection
por: Alizadeh-Tabrizi, Nazli, et al.
Publicado: (2021)

Dysregulated Iron Homeostasis as Common Disease Etiology and Promising Therapeutic Target
por: Holbein, Bruce E., et al.
Publicado: (2023)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles’ heel of antibiotic-resistant microbes
por: Holbein, Bruce E., et al.
Publicado: (2021)

Preventive Therapy of Experimental Colitis with Selected iron Chelators and Anti-oxidants
por: Minaiyan, Mohsen, et al.
Publicado: (2012)

Effect of iron chelation on anti-pseudomonal activity of doxycycline
por: Faure, ME, et al.
Publicado: (2021)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach
por: Islam, Sufia, et al.
Publicado: (2022)

Bacterial Resistance in Pneumonia in Developing Countries—A Role for Iron Chelation
por: Islam, Sufia, et al.
Publicado: (2019)

Dexras1 Deletion and Iron Chelation Promote Neuroprotection in Experimental Optic Neuritis
por: Khan, Reas S., et al.
Publicado: (2019)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Reversing oncogenic transformation with iron chelation
por: Abdelaal, Gina, et al.
Publicado: (2021)

Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)

A Review on Iron Chelators in Treatment of Iron Overload Syndromes
por: Mobarra, Naser, et al.
Publicado: (2016)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Chelators in the Treatment of Iron Accumulation in Parkinson's Disease
por: Mounsey, Ross B., et al.
Publicado: (2012)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Oxidation-Induced Degradable Nanogels for Iron Chelation
por: Liu, Zhi, et al.
Publicado: (2016)

Iron Chelation Resulting in Renal Phosphate Wasting
por: Cheddani, Lynda, et al.
Publicado: (2017)

Potential Treatment of Retinal Diseases with Iron Chelators
por: Shu, Wanting, et al.
Publicado: (2018)

Controversies on the Consequences of Iron Overload and Chelation in MDS
por: Vinchi, Francesca, et al.
Publicado: (2020)

Conformational Stability Effect of Polymeric Iron Chelators
por: Qian, Jian, et al.
Publicado: (2019)

Adherence to Iron Chelation Therapy and Its Determinants
por: Sidhu, Sukhmani, et al.
Publicado: (2021)

Benefits of Iron Chelators in the Treatment of Parkinson’s Disease
por: Zeng, Xiaoyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cbom32rlaqnd25loqs05o728vm